The Oncologist's View: Targeted Therapies in Advanced Renal Cell Carcinoma

European Urology, Supplements

Volumn 7, Issue 2, 2008, Pages 55-62

  Bellmunt, Joaquim ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Compliance; Metastatic renal cell carcinoma; Sunitinib; Tyrosine kinase inhibitor; VEGF

Indexed keywords

ALPHA INTERFERON; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 3A4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; KETOCONAZOLE; MAMMALIAN TARGET OF RAPAMYCIN; METHYLPHENIDATE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RIFAMPICIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRICYCLIC ANTIDEPRESSANT AGENT; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANEMIA; CANCER FATIGUE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EMOTIONAL DISORDER; EMOTIONAL STRESS; FATIGUE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LEUKOPENIA; MEDICAL SPECIALIST; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; NUTRITIONAL SUPPORT; ONCOLOGY; PATIENT EDUCATION; PIGMENT DISORDER; PRIORITY JOURNAL; RELAXATION TRAINING; REVIEW; SLEEP DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 38549180269     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.12.004     Document Type: Review

References (23)

1. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
2. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80 (1997) 1198-1220
3. Roskoski Jr. R. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356 (2007) 323-328
4. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
5. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
6. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
7. Motzer R.J., and Russo P. Systemic therapy for renal cell carcinoma. J Urol 163 (2000) 408-417
8. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
9. Rosenberg JE, Motzer J, Michaelson BG, et al. Sunitinib therapy for patients with metastatic renal cell carcinoma: updated results of two phase II trials and prognostic factor analysis for survival. American Society of Clinical Oncology 2007. Abstract no. 5095.
10. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
11. Motzer RJ, Figlin TE, Hutson P, et al. Sunitinib versus interferon alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors. American Society of Clinical Oncology 2007. Abstract no. 5024.
12. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
13. Hudes G., Carducci M., Tomczak P., et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol, ASCO Annual Meeting Proceedings Part I 24 (2006) LBA4
14. Bellmunt J., Montagut C., Albiol S., et al. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 99 (2007) 274-280
15. National Comprehensive Cancer Network (NCCN) TNCPGiO. Cancer-related fatigue. http://www.nccn.org/professionals/physician_gls/default.asp Accessed on: 23 July 2007.
16. Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99 (2007) 81-83
17. Izzedine H., Rixe O., Billemont B., Baumelou A., and Deray G. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50 (2007) 203-218
18. Mollnau H., Wendt M., Szocs K., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90 (2002) E58-E65
19. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280 (2001) C1375-C1386
20. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
21. National Cancer Institute. Common terminology criteria for adverse events v 3.0 (CTCAE). http://ctep.cancer.gov/reporting/ctc_v30.html Accessed on 24 July 2007.
22. Wood L.S. Managing the side effects of sorafenib and sunitinib. Community Oncol 3 (2006) 558-562
23. Force T., Krause D.S., and Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7 (2007) 332-344